State Street Corp ownership in IOVA / Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc.

US ˙ NasdaqGM ˙ US4622601007

Security	IOVA / Iovance Biotherapeutics, Inc.
Institution	State Street Corp
Latest Disclosed Ownership	17,448,108 shares
Ownership	4.20%

2026-05-12 - State Street Corp has filed an SCHEDULE 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 17,448,108 shares of Iovance Biotherapeutics, Inc. (US:IOVA). This represents 4.2 percent ownership of the company. In their previous filing dated 2026-02-09 , State Street Corp had reported owning 20,161,445 shares, indicating a decrease of -13.46 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File Date	Effective Date	Form	Prev Shares	Latest Shares	ΔShares (Percent)	Ownership (Percent)	ΔOwnership (Percent)
2026-05-12	2026-05-12	13G	20,161,445	17,448,108	-13.46	4.20	-17.65
2026-02-09	2026-02-09	13G	13,201,978	20,161,445	52.72	5.10	15.91
2024-10-18	2024-10-18	13G/A	16,424,388	13,201,978	-19.62	4.40	-31.46
2024-01-25	2024-01-25	13G/A	14,715,475	16,424,388	11.61	6.42	-31.12
2023-02-02	2023-02-02	13G		14,715,475		9.32

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-05-15	2026-03-31	13F	IOVANCE BIOTHERAPEUTICS	COM	462260100	17,448,108	-2,713,337	-13.46	61,243	11.27	0.0021
2026-02-13	2025-12-31	13F	IOVANCE BIOTHERAPEUTICS	COM	462260100	20,161,445	6,851,486	51.48	55,041	90.57	0.0018
2025-11-14	2025-09-30	13F	IOVANCE BIOTHERAPEUTICS	COM	462260100	13,309,959	3,419,434	34.57	28,883	69.78	0.0010
2025-08-14	2025-06-30	13F	IOVANCE BIOTHERAPEUTICS	COM	462260100	9,890,525	-1,150,797	-10.42	17,012	-53.73	0.0006
2025-05-15	2025-03-31	13F	IOVANCE BIOTHERAPEUTICS	COM	462260100	11,041,322	-1,207,960	-9.86	36,768	-59.44	0.0015
2025-02-14	2024-12-31	13F	IOVANCE BIOTHERAPEUTICS	COM	462260100	12,249,282	-952,696	-7.22	90,645	-26.88	0.0036
2024-11-14	2024-09-30	13F	IOVANCE BIOTHERAPEUTICS	COM	462260100	13,201,978	576,801	4.57	123,967	22.43	0.0050
2024-08-14	2024-06-30	13F	IOVANCE BIOTHERAPEUTICS	COM	462260100	12,625,177	2,222,458	21.36	101,254	-34.32	0.0044
2024-05-15	2024-03-31	13F	IOVANCE BIOTHERAPEUTICS	COM	462260100	10,402,719	-6,021,669	-36.66	154,168	15.46	0.0069
2024-02-14	2023-12-31	13F	IOVANCE BIOTHERAPEUTICS	COM	462260100	16,424,388	-307,881	-1.84	133,530	75.40	0.0065
2023-11-14	2023-09-30	13F	IOVANCE BIOTHERAPEUTICS	COM	462260100	16,732,269	3,166,471	23.34	76,132	-20.28	0.0042
2023-08-14	2023-06-30	13F	IOVANCE BIOTHERAPEUTICS	COM	462260100	13,565,798	-167,235	-1.22	95,503	13.82	0.0050
2023-05-15	2023-03-31	13F	IOVANCE BIOTHERAPEUTICS	COM	462260100	13,733,033	-982,442	-6.68	83,909	-10.77	0.0047
2023-05-15	2022-12-31	13F/A-99	IOVANCE BIOTHERAPEUTICS	COM	462260100	14,715,475	4,783,323	48.16	94,032	-1.18	0.0055
2023-05-15	2022-12-31	13F	IOVANCE BIOTHERAPEUTICS	COM	462260100	14,715,475	4,783,323		94,032		0.0055
2022-11-15	2022-09-30	13F	IOVANCE BIOTHERAPEUTICS	COM	462260100	9,932,152	-1,838,599	-15.62	95,150	-26.78	0.0060
2022-08-15	2022-06-30	13F	IOVANCE BIOTHERAPEUTICS	COM	462260100	11,770,751	4,925,025	71.94	129,949	14.01	0.0078
2022-05-16	2022-03-31	13F	IOVANCE BIOTHERAPEUTICS	COM	462260100	6,845,726	1,752,044	34.40	113,981	17.22	0.0056
2022-02-14	2021-12-31	13F	IOVANCE BIOTHERAPEUTICS	COM	462260100	5,093,682	705,576	16.08	97,238	-10.14	0.0046
2021-11-15	2021-09-30	13F	IOVANCE BIOTHERAPEUTICS	COM	462260100	4,388,106	445,433	11.30	108,211	5.48	0.0057
2021-08-16	2021-06-30	13F	IOVANCE BIOTHERAPEUTICS	COM	462260100	3,942,673	867,022	28.19	102,588	5.35	0.0054
2021-07-09	2021-03-31	13F/A-1	IOVANCE BIOTHERAPEUTICS	COM	462260100	3,075,651	178,572	6.16	97,375	-27.56	0.0056
2021-05-17	2021-03-31	13F	IOVANCE BIOTHERAPEUTICS	COM	462260100	3,075,651	178,572		97,375		0.0056
2021-02-16	2020-12-31	13F	IOVANCE BIOTHERAPEUTICS	COM	462260100	2,897,079	-272,482	-8.60	134,424	28.83	0.0082
2020-11-10	2020-09-30	13F	IOVANCE BIOTHERAPEUTICS	COM	462260100	3,169,561	-233,112	-6.85	104,342	11.71	0.0071
2020-08-14	2020-06-30	13F	IOVANCE BIOTHERAPEUTICS	COM	462260100	3,402,673	-995,498	-22.63	93,403	-29.06	0.0068
2020-06-19	2020-03-31	13F/A-1	IOVANCE BIOTHERAPEUTICS	COM	462260100	4,398,171	73,995	1.71	131,659	10.00	0.0115
2020-05-11	2020-03-31	13F	IOVANCE BIOTHERAPEUTICS	COM	462260100	4,398,171	73,995		131,659		11,562.3112
2020-02-06	2019-12-31	13F	IOVANCE BIOTHERAPEUTICS	COM	462260100	4,324,176	-434,043	-9.12	119,693	38.21	0.0082
2019-11-14	2019-09-30	13F	IOVANCE BIOTHERAPEUTICS	COM	462260100	4,758,219	1,336,353	39.05	86,600	3.21	0.0065
2019-08-14	2019-06-30	13F	IOVANCE BIOTHERAPEUTICS	COM	462260100	3,421,866	-641,369	-15.78	83,904	117.14	0.0063
2019-05-15	2019-03-31	13F	IOVANCE BIOTHERAPEUTICS	COM	462260100	4,063,235	-416,017	-9.29	38,641	-2.52	0.0030
2019-02-12	2018-12-31	13F	IOVANCE BIOTHERAPEUTICS	COM	462260100	4,479,252	496,690	12.47	39,641	-11.53	0.0036
2018-11-09	2018-09-30	13F	IOVANCE BIOTHERAPEUTICS	Common equity shares	462260100	3,982,562	127,418	3.31	44,806	-9.21	0.0034
2018-08-14	2018-06-30	13F	IOVANCE BIOTHERAPEUTICS	Common equity shares	462260100	3,855,144	1,652,863	75.05	49,350	32.60	0.0041
2018-05-15	2018-03-31	13F	IOVANCE BIOTHERAPEUTICS	Common equity shares	462260100	2,202,281	291,769	15.27	37,217	143.55	0.0032
2018-02-14	2017-12-31	13F	IOVANCE BIOTHERAPEUTICS	Common equity shares	462260100	1,910,512	894,958	88.13	15,281	94.14	0.0012
2017-11-14	2017-09-30	13F	IOVANCE BIOTHERAPEUTICS	Common equity shares	462260100	1,015,554	24,163	2.44	7,871	8.03	0.0007
2017-08-14	2017-06-30	13F	IOVANCE BIOTHERAPEUTICS	Common equity shares	462260100	991,391	66,560	7.20	7,286	5.73	0.0006
2017-05-15	2017-03-31	13F	LION BIOTECHNOLOGIES	Common equity shares	53619R102	924,831	61,248	7.09	6,891	14.77	0.0006
2017-02-09	2016-12-31	13F	LION BIOTECHNOLOGIES	Common equity shares	53619R102	863,583	143,220	19.88	6,004	1.32	0.0006
2017-01-13	2016-09-30	13F/A-1	LION BIOTECHNOLOGIES	Common equity shares	53619R102	720,363	27,579	3.98	5,926	5.61	0.0006
2016-11-14	2016-09-30	13F	LION BIOTECHNOLOGIES	Common equity shares	53619R102	720,363			5,926
2016-08-12	2016-06-30	13F	LION BIOTECHNOLOGIES	Common equity shares	53619R102	692,784	22,681	3.38	5,611	64.79	0.0006
2016-05-20	2016-03-31	13F/A-1	LION BIOTECHNOLOGIES	Common equity shares	53619R102	670,103	1,206	0.18	3,405	-34.05	0.0004
2016-05-12	2016-03-31	13F	LION BIOTECHNOLOGIES	Common equity shares	53619R102	670,103			3,405
2016-02-16	2015-12-31	13F	LION BIOTECHNOLOGIES	Common equity shares	53619R102	668,897	86,672	14.89	5,163	53.89	0.0006
2015-11-16	2015-09-30	13F	LION BIOTECHNOLOGIES	Common equity shares	53619R102	582,225	110,736	23.49	3,355	-22.45	0.0004
2015-08-13	2015-06-30	13F	LION BIOTECHNOLOGIES	Common equity shares	53619R102	471,489	471,489		4,326		0.0005

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.